Structural and functional insights into targeting hTERT G-quadruplex by levo-Tetrahydropalmatine in the non-small

Huanfeng Ye1, Hong Zhang2, Hong Chen3

  • 1Beijing National Laboratory for Molecular Sciences, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China.

PubMed

Insights

Levo-tetrahydropalmatine and its derivatives bind the human telomerase reverse transcriptase (hTERT) G-quadruplex, suppressing gene expression and showing potent antitumor activity against non-small cell lung cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The G-quadruplex structure in the human telomerase reverse transcriptase (hTERT) promoter is a potential cancer therapeutic target.
  • Selective ligand development for this target is crucial but challenging.

Purpose of the Study:

  • To identify novel ligands for the hTERT G-quadruplex.
  • To investigate the binding mechanism and antitumor potential of these ligands.

Main Methods:

  • Fluorescence spectroscopy, UV-visible absorption, circular dichroism (CD), CD-melting assays, and electrophoretic mobility shift assays (EMSA) were used to study ligand binding.
  • Molecular docking was employed to predict binding modes.
  • Cellular assays and in vivo models were used to evaluate antitumor activity.

Main Results:

  • Levo-tetrahydropalmatine (l-THP) and its derivatives (M1, M2) were identified as novel ligands with binding affinity and selectivity for the hTERT G-quadruplex.
  • These compounds preferentially bind to the junction between G-tracts, recognizing cytosine at position 21.
  • l-THP, M1, and M2 significantly suppressed hTERT mRNA expression and demonstrated potent antitumor activity in lung cancer cells and xenograft models.

Conclusions:

  • l-THP and its derivatives are promising lead compounds for non-small cell lung cancer (NSCLC) chemotherapeutics.
  • These findings provide mechanistic insights into their potent antitumor effects.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
395